Chapter: 1 INTRODUCTION
1.1 Report description
1.2 Key benefits
1.3 Key market segment
1.4 Research methodology
1.4.1 Secondary research
1.4.2 Primary research
1.4.3 Analyst tools and models

Chapter: 2 EXECUTIVE SUMMARY

Chapter: 3 MARKET OVERVIEW
3.1 Market definition
3.2 Need for glucose monitoring systems
3.2.1 Diabetes - a pandemic
3.2.1.1 Type 1 diabetes
3.2.1.2 Type-2 diabetes
3.2.1.3 Pre-diabetes and Gestational Diabetes Mellitus (GDM)
3.2.1.4 Gestational Diabetes Mellitus (GDM)
3.2.1.5 Secondary diabetes
3.2.2 Global healthcare expenditure on diabetes
3.3 Emerging technologies in CGMS
3.3.1 Smartphone-connected CGMS
3.3.2 Wearable and smartphone-connected CGMS
3.3.3 Non-invasive CGMS
3.3.4 Invasive CGMS in the R&D pipeline
3.3.5 'Smart' diabetes management solution - Bionic Pancreas
3.4 CGMS - Prime end user segments
3.4.1 CGMS - crucial need in Intensive Care Units (ICUs)
3.4.1.1 ?Stress Hyperglycemia' - common occurrence in ICUs
3.4.1.2 Non-standardization and erroneous glycemic control across ICUs
3.4.2 Benefits and factors driving adoption of CGMS in ICUs
3.4.2.1 CGMS aid in Tight Glycemic Control in ICUs
3.4.2.2 Cost benefits from usage of CGMS
3.4.2.3 POC Glucometers less effective in ICUs - as compared to CGMS
3.4.2.4 CGMS - most preferred by ICU staff
3.5 Key findings
3.5.1 Top impacting factors
3.5.2 Top investment pockets
3.5.2.1 CGMS market -By End User Segments
3.5.2.2 CGMS market - by geography
3.5.3 Top winning strategies
3.6 Value chain analysis
3.7 Market share analysis, 2014
3.8 Government regulations
3.9 Reimbursement scenario
3.10 Drivers
3.10.1 Rise in incidence of diabetes globally
3.10.2 Inherent benefits of CGMS over POC glucometers - drive market growth
3.10.3 Increase in awareness in developing and underdeveloped economies
3.10.4 Focus on developing OTC/POC CGMS catering to new end user segment - future growth driver
3.10.5 FDA, U.S. approval of Bionic Pancreas - future growth driver
3.11 Restraints
3.11.1 Stringent regulatory requirements
3.11.2 Inadequate reimbursements-a barrier in CGMS adoption
3.11.3 Accuracy and cost-a hindrance in continuing use of CGMS
3.12 Opportunities
3.12.1 Higher adoption rate of CGMS in ICUs
3.12.2 OTC/POC CGMS - expanded product applications/usage
3.12.3 ?Undiagnosed' patient population
3.13 Winning strategies for MNCs for entering emerging markets
3.13.1 Gaining CE approvals for a speedier entry into Asia--Pacific and LAMEA markets
3.13.2 Forming distribution alliances to enhance geographical reach
3.13.3 Raising end-user awareness and competitive product pricing

Chapter: 4 CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET- BY COMPONENTS
4.1 Stand-alone and Integrated CGM systems
4.1.1 Market size and forecast
4.2 Sensors
4.2.1 Key market trends
4.2.1.1 Non-invasive glucose sensors
4.2.1.2 Subcutaneous sensors (Minimally Invasive Sensors)
4.2.1.3 Conventional technology-holter-yype retrospective sensors
4.2.1.4 Advanced technology-Real-Time sensors
4.2.2 Key growth factors and opportunities
4.2.3 Market size and forecast
4.3 Transmitters & Receivers
4.3.1 Key market trends
4.3.2 Key growth factors and opportunities
4.3.3 Market size and forecast
4.4 Integrated Insulin pumps
4.4.1 Overview
4.4.2 Key market trends
4.4.3 Key growth factors and opportunities
4.4.4 Market size and forecast

Chapter: 5 CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET - BY END USER SEGMENT
5.1 Market size and forecast
5.2 Diagnostic centers/clinics
5.2.1 Market size and forecast
5.3 ICUs
5.3.1 Market size and forecast
5.4 Home healthcare
5.4.1 Market size and forecast

Chapter: 6 CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET - BY AGE DEMOGRAPHICS
6.1 Juveniles
6.2 Gen X
6.3 Geriatrics / undiagnosed

Chapter: 7 CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET- BY GEOGRAPHY
7.1 North America
7.1.1 Market size and forecast
7.1.2 U.S.
7.1.3 Canada
7.1.4 Mexico
7.2 Europe
7.2.1 Key market trends
7.2.2 Key growth factors and opportunities
7.2.4 France
7.2.4.1 Key market trends
7.2.4.2 Key growth factors and opportunities
7.2.5 Germany
7.2.5.1 Key market trends
7.2.5.2 Key growth factors and opportunities
7.2.6 U.K.
7.2.6.1 Key market trends
7.2.6.2 Key growth factors and opportunities
7.2.7 Other European countries
7.3 Asia-Pacific
7.3.1 Market size and forecast
7.3.2 India
7.3.2.1 Key market trends
7.3.3 Australia
7.3.3.1 Key market trends
7.3.4 China
7.3.4.1 Key market trends
7.3.5 Other APAC countries
7.4 LAMEA
7.4.1 Overview
7.4.2 Market size and forecast
7.4.3 Gulf Cooperation Council (GCC)
7.4.3.1 Key market trends

Chapter: 8 COMPANY PROFILES
8.1 Medtronic Plc.
8.1.1 Company overview
8.1.2 Business performance
8.1.3 Strategic moves and developments
8.1.3.1 Principal strategies: product launch
8.1.3.2 Secondary strategies: approval
8.1.3.3 Other strategies: strategic alliance and collaboration
8.1.4 SWOT analysis of Medtronic Plc
8.2 Dexcom Inc.
8.2.1 Company overview
8.2.2 Business performance
8.2.3 Strategic moves and developments
8.2.3.1 Principal strategies: agreement/partnership
8.2.3.2 Secondary strategies: approval
8.2.3.3 Other strategies: acquisition
8.2.4 SWOT analysis of Dexcom
8.3 Abbott Diabetic Care (Abbott Laboratories)
8.3.1 Company overview
8.3.2 Business performance
8.3.3 Strategic moves and developments
8.3.4 SWOT analysis of Abbott diabetic care
8.4 Animas Corporation
8.4.1 Company overview
8.4.2 Strategic moves and developments
8.4.3 SWOT analysis of Animas Corporation
8.5 Echo Therapeutics
8.5.1 Company Overview
8.5.2 Strategic moves and development
8.5.3 SWOT Analysis of Echo Therapeutics
8.6 Insulet Corporation
8.6.1 Company overview
8.6.2 Strategic moves and developments
8.6.3 SWOT analysis of INSULET Corporation
8.7 Glysens Inc.
8.7.1 Company overview
8.7.2 Strategic moves and developments
8.7.3 SWOT Analysis of Glysens Inc.
8.8 Senseonics, Inc.
8.8.1 Company overview
8.8.2 Strategic moves and development
8.8.3 SWOT analysis of Senseonics, Inc.

List of Figures

FIG. 1 PREVALENCE OF TYPE 1 DIABETES (AGED <15 YEARS), BY GEOGRAPHY
FIG. 2 GLOBAL PREVALENCE OF TYPE-2 DIABETES (2000) AND ESTIMATED PREVALENCE (2030)
FIG. 3 PREDISPOSITION AND RISK FACTORS - SIMILAR FOR PRE-DIABETES AND TYPE-2 DIABETES
FIG. 4 GLOBAL FINANCIAL BURDEN OF DIABETES ATTRIBUTED TO AGE GROUP (20-79 YEARS)
FIG. 5 GLOBAL FINANCIAL BURDEN OF DIABETES, BY GEOGRAPHY
FIG. 6 OCCURENCE OF HYPERGLYCEMIA IN ICUS
FIG. 7 TOP FACTORS IMPACTING CGMS MARKET, 2014-2021
FIG. 8 TOP INVESTMENT POCKETS IN CGMS END USER SEGMENT MARKETS
FIG. 9 TOP INVESTMENT POCKETS IN CGMS GEOGRAPHY MARKETS
FIG. 10 TOP WINNING STRATEGIES IN CGMS MARKET, 2010 - 2014
FIG. 11 TOP WINNING STRATEGY IN CGMS MARKET BY YEAR, 2010-2014 (SEPTEMBER)
FIG. 13 MARKET SHARE ANALYSIS OF GLOBAL CGMS MARKET 2014
FIG. 14 GLOBAL INCIDENCE OF DIABETES, BY GEOGRAPHY (2000, 2011 AND 2030)
FIG. 15 PATIENT POPULATION UNDIAGNOSED FOR DIABETES , 2013 (MILLION)
FIG. 16 GLOBAL CGMS MARKET BY END-USER DEMOGRAPHICS, 2014 AND 2021
FIG. 17 CASES OF DIABETES BY AGE GROUP IN NORTH AMERICA (1,000S) (2013)
FIG. 18 CASES OF DIABETES BY AGE GROUP IN EUROPE (1,000S) (2013)
FIG. 19 MEDTRONIC REVENUE BY GEOGRAPHY (2014)
FIG. 20 SWOT ANALYSIS OF MEDTRONIC PLC
FIG. 21 SWOT ANALYSIS OF DEXCOM INC.
FIG. 22 REVENUE BY BUSINESS SEGMENT (2014)
FIG. 23 SWOT ANALYSIS OF ABBOTT DIABETIC CARE
FIG. 24 SWOT ANALYSIS OF ANIMAS CORPORATION
FIG. 25 SWOT ANALYSIS OF ECHO THERAPEUTICS
FIG. 26 SWOT ANALYSIS OF INSULET CORPORATION
FIG. 27 SWOT ANALASIS OF GLYSEN INCORPORATED
FIG. 28 SWOT ANALYSIS OF SENSEONICS, INC.